Business Context and Reporting Period
This Form 8-K Current Report was filed by ENDRA Life Sciences Inc. on June 22, 2017. The company is incorporated in Delaware and is designated as an emerging growth company. The report addresses a specific corporate event regarding the separation of its trading units.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is a current report focused solely on a corporate event and does not provide quantitative financial metrics.
Material Changes
The primary material event reported is the anticipated separation of the company's units, scheduled to occur on June 28, 2017, prior to the market open. Following this separation:
- Common stock will trade separately under the symbol NDRA.
- Warrants will trade separately under the symbol NDRAW.
- Trading of the combined units under the symbol NDRAU will be suspended.
Guidance, Outlook, and Risks
The filing incorporates by reference a press release (Exhibit 99.1) detailing the unit separation. No forward-looking guidance, management commentary on financial performance, specific risk factors, or contingencies are disclosed within the text of this 8-K. The document serves strictly to notify the market of the upcoming change in trading symbols.
Key Facts for Investor Verification
- Verify the exact timing of the unit separation on June 28, 2017, to ensure proper trading of the new symbols.
- Confirm the suspension of trading for the unit symbol NDRAU effective June 28, 2017.
- Review the attached press release (Exhibit 99.1) for any additional details regarding the separation mechanics not included in the 8-K summary.